Anis Fahandej-Sadi | TLDR Biotech

Oliver Buchannon

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 9 - 12, 2026

Apr 13, 2026

•

7 min read

Biotech & Pharma Updates | April 9 - 12, 2026

🧬 Sun Pharma readies $12B binding offer to acquire women's health company Organon amid competing bids, Vivatides Therapeutics raises $54M Series A for RNA delivery beyond the liver, GSK advances mocertatug rezetecan (Mo-Rez) targeting B7-H4 to Ph3 trials for ovarian and endometrial cancers

Anis Fahandej-Sadi

Long Form Content

Biopunk & Community Labs: The Future For Biotech?

Apr 11, 2026

•

24 min read

Biopunk & Community Labs: The Future For Biotech?

Why the biotech of the future might be a lot smaller and a lot more nimble

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 8 - 9, 2026

Apr 10, 2026

•

8 min read

Biotech & Pharma Updates | April 8 - 9, 2026

🧬 Eli Lilly launches obesity pill Foundayo at $149 - intensifying GLP-1 competition with Novo Nordisk's Wegovy, Genentech receives FDA approval for updated Vabysmo (faricimab-svoa) label extending macular edema treatment beyond six months, Avalyn Pharma plans IPO - developing inhalable IPF treatments for lung disease, Invivyd prepares VMS063 antibody targeting fusion protein for Ph1 testing in measles treatment and prevention, Boehringer Ingelheim hands Click Therapeutics marketing rights to schizophrenia PDT CT-155 + $50M investment

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 7 - 8, 2026

Apr 9, 2026

•

8 min read

Biotech & Pharma Updates | April 7 - 8, 2026

🧬 Jeito Capital raises $1.2B fund - investing in European clinical-stage drugmakers, Shionogi lands US BARDA contract for Fetroja antibiotic manufacturing - $482M potential value, Gilead Sciences pauses M&A after acquiring Arcellx + Ouro Medicines + and Tubulis within six weeks

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 6 - 7, 2026

Apr 8, 2026

•

7 min read

Biotech & Pharma Updates | April 6 - 7, 2026

🧬 Gilead Sciences to acquire German biotech Tubulis for $3.1B upfront in ADC deal, E2 raises $80M Series C for next-gen thrombectomy treatment commercialization, Vertex Pharmaceuticals + Halozyme partner on Hypercon drug delivery technology - $15M upfront plus milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 5 - 6, 2026

Apr 7, 2026

•

7 min read

Biotech & Pharma Updates | April 5 - 6, 2026

🧬 Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in “surprising” acquisition - gaining rare obesity disorder drug Vykat XR, Stipple Bio emerges from stealth with $100M Series A to develop tumor-specific epitope-targeting ADCs, Amgen's subcutaneous Tepezza (teprotumumab) meets Ph3 endpoints for thyroid eye disease treatment

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 1 - 5, 2026

Apr 6, 2026

•

9 min read

Biotech & Pharma Updates | April 1 - 5, 2026

🧬 Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities, Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison, Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050 - €5M ($5.77M) plus milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 31 - April 1, 2026

Apr 2, 2026

•

8 min read

Biotech & Pharma Updates | March 31 - April 1, 2026

🧬 Eli Lilly's Foundayo (orforglipron) wins FDA approval for obesity treatment following Ph3 success, Korsana Biosciences to go public via Cyclerion Therapeutics reverse merger with $380M funding, Syneron Bio raises $150M Series B, advancing macrocyclic peptide drug discovery platform

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 30 - 31, 2026

Apr 1, 2026

•

9 min read

Biotech & Pharma Updates | March 30 - 31, 2026

🧬 Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B to enter sleep disorder market - ultimately challenging Takeda, Ambrosia Biosciences raises $100M Series B - developing oral weight-loss medications, BMS + Faro partner on multi-year AI clinical trial protocol improvement agreement

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 29 - 30, 2026

Mar 31, 2026

•

8 min read

Biotech & Pharma Updates | March 29 - 30, 2026

🧬 Blackstone closes $6.3B fund for life sciences investing and partnerships, Royalty Pharma's $500M investment to Johnson & Johnson to co-fund autoimmune antibody JNJ-4804, FDA approves Biogen's high-dose Spinraza ASO targeting SMN2 for SMA

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 26 - 29, 2026

Mar 30, 2026

•

8 min read

Biotech & Pharma Updates | March 26 - 29, 2026

🧬 Eli Lilly + Insilico Medicine expand AI drug discovery collaboration - $115M upfront + $2.75B total value, AstraZeneca's tozorakimab hits Ph3 endpoints for chronic obstructive pulmonary disease targeting IL-33 pathway, Terrestrial Bio raises $50M Series C - developing microarray patch therapeutic delivery platform

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 25 - 26, 2026

Mar 27, 2026

•

7 min read

Biotech & Pharma Updates | March 25 - 26, 2026

🧬 Pinnacle Medicines raises $89M Series B - advancing oral peptide therapeutics platform, Neion Bio emerges from stealth with egg-based biosimilar partnership to develop three monoclonal antibodies, Insilico Medicine + Tenacia Biotechnology expand AI-driven CNS collaboration with $94.75M deal value

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 24 - 25, 2026

Mar 26, 2026

•

9 min read

Biotech & Pharma Updates | March 24 - 25, 2026

🧬 Merck & Co. to acquire Terns Pharmaceuticals for $6.7B - targeting TERN-701 leukemia drug ahead of Keytruda cliff, Biogen + Alteogen partner on subcutaneous delivery tech - $20M upfront + $559M potential milestones, Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) wins FDA accelerated approval for Hunter syndrome neurologic manifestations

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 23 - 24, 2026

Mar 25, 2026

•

8 min read

Biotech & Pharma Updates | March 23 - 24, 2026

🧬 UCB to build $2B biologics manufacturing facility near Atlanta headquarters, creating 330 jobs, Ocugen advances OCU410 gene therapy targeting RORA to Ph3 for geographic atrophy following positive Ph2 results, Merck & Co. + Quotient Therapeutics partner on IBD drug discovery - $20M upfront + $2.2B milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 22 - 23

Mar 24, 2026

•

8 min read

Biotech & Pharma Updates | March 22 - 23

🧬 Novartis commits $480M to expand manufacturing in Beijing and R&D operations in Shanghai, Oryon Cell Therapies raises $42M Series A - Parkinson's cell therapy replacing dopaminergic neurons, Sanofi + Kali Therapeutics partner on autoimmune tri-specific antibody KT501 - $180M upfront + $1.05B milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 19 - 22, 2026

Mar 23, 2026

•

7 min read

Biotech & Pharma Updates | March 19 - 22, 2026

🧬 Earendil Labs raises $787M funding - AI-powered drugmaker developing biologics for autoimmune conditions and cancer, Novartis acquires Synnovation Therapeutics' Pikavation for $2B upfront to expand PI3Kα breast cancer portfolio, Bristol Myers Squibb's Opdivo (nivolumab) wins FDA approval for treatment-naïve classical Hodgkin lymphoma

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 18 - 19, 2026

Mar 20, 2026

•

8 min read

Biotech & Pharma Updates | March 18 - 19, 2026

🧬 Novo Nordisk's Wegovy HD (semaglutide) wins FDA approval for obesity treatment under priority voucher program, Fauna Bio + Eli Lilly achieve obesity target milestone using hibernation-inspired AI platform - triggers payment, Congruence Therapeutics raises $39.5M financing to advance small molecule correctors pipeline

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 17 - 18, 2026

Mar 19, 2026

•

8 min read

Biotech & Pharma Updates | March 17 - 18, 2026

🧬 Crossbow Therapeutics raises $77M Series B - developing next-generation cancer immunotherapies, TerraPower commits $450M to build Philadelphia radioisotope production plant - boosting actinium-225 capacity 20-fold, Johnson & Johnson's Icotyde (icotrokinra) wins FDA approval for moderate-to-severe plaque psoriasis targeting interleukin-23

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 16 - 17, 2026

Mar 18, 2026

•

8 min read

Biotech & Pharma Updates | March 16 - 17, 2026

🧬 BioVie’s Option Therapeutics plans $20M IPO - developing liver disease drug treatment, R1 Therapeutics emerges with $77.5M series A funding for novel CKD phosphate control drug AP306, Pfizer's atirmociclib hits Ph2 goal reducing death risk 40% in advanced breast cancer patients

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 15 - 16, 2026

Mar 17, 2026

•

8 min read

Biotech & Pharma Updates | March 15 - 16, 2026

🧬 Roche + Nvidia expand AI partnership with 2,176 Blackwell GPUs for drug and diagnostic development, Federal judge blocks RFK Jr.'s childhood vaccine schedule changes + halts CDC advisory panel appointments, Unnatural Products raises $45M Series B, macrocyclic peptides for undruggable targets, CytomX Therapeutics reports positive Ph1 data for Varseta-M antibody-drug conjugate in colorectal cancer, Eli Lilly's Ebglyss IL-13 inhibitor hits Ph3 endpoints in pediatric atopic dermatitis - setting up label expansion, AstraZeneca's Imfinzi (durvalumab) wins EU approval for resectable gastric and gastroesophageal junction cancers following Ph3 success

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 12 - 15, 2026

Mar 16, 2026

•

6 min read

Biotech & Pharma Updates | March 12 - 15, 2026

🧬 Sana Biotechnology's UP421 islet cell therapy shows sustained insulin production at 14 months in Type 1 diabetes patient, Gubra launches Gubra Ventures unit to incubate new biotechs using Roivant-like asset-centric company model, GSK's Arexvy wins FDA label expansion for respiratory syncytial virus in high-risk adults under 50

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 11 - 12, 2026

Mar 13, 2026

•

7 min read

Biotech & Pharma Updates | March 11 - 12, 2026

🧬 Eli Lilly invests $126M to expand Japan manufacturing plant for diabetes and obesity medicines, Regenxbio reports positive Ph1/Ph2 data for RGX-202 gene therapy in Duchenne muscular dystrophy, Enodia Therapeutics pays for Kezar Life Sciences preclinical protein degrader program - $1M upfront + $127M milestones

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 10 - 11, 2026

Mar 12, 2026

•

9 min read

Biotech & Pharma Updates | March 10 - 11, 2026

🧬 FDA launches unified Adverse Event Monitoring System replacing fragmented databases - saving $120M over five years, Eli Lilly invests $3B in China operations to boost orforglipron weight loss pill manufacturing capacity, Salspera plans $91M IPO to fund phase 3 salmonella-based cancer therapy studies, Vima Therapeutics raises $100M Series B - oral drug for movement disorders, UCB's Bimzelx (bimekizumab) shows Ph3 superiority over AbbVie's Skyrizi in psoriatic arthritis head-to-head trial

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 9 - 10, 2026

Mar 11, 2026

•

9 min read

Biotech & Pharma Updates | March 9 - 10, 2026

🧬 Breakout Ventures raises $114M third fund - supporting AI-focused early-stage biotechs, CSL breaks ground on $1.5B plasma medicine plant expansion in Illinois - creating 300 jobs by 2031, GSK's Wellcovorin (leucovorin) wins FDA approval for cerebral folate deficiency targeting folate receptor 1

Anis Fahandej-Sadi

Biotech & Pharma Updates | March 8 - 9, 2026

Mar 10, 2026

•

9 min read

Biotech & Pharma Updates | March 8 - 9, 2026

🧬 Novo Nordisk + Hims & Hers partner to sell GLP-1 drugs Ozempic and Wegovy, ending lawsuit dispute, Alfasigma + GSK strike $690M deal for linerixibat itching treatment awaiting FDA approval, Regeneron Pharmaceuticals reports positive Ph3 data for olatorepatide (olatorepatide) targeting GLP-1/GIP receptors for obesity treatment, Relmada Therapeutics raises $160M private placement, advancing oncology and CNS therapies, FDA's Prasad departure boosts rare disease biotechs uniQure, Replimune, Disc Medicine stock prices premarket Monday

Anis Fahandej-Sadi